CJC-1295 (without DAC / Mod GRF 1-29) vs MOTS-c

Mechanism

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

• Flushing post-injection
• Head rush
• Hunger increase
• Water retention (mild)
• Tingling in extremities

Contraindications

• Active cancer
• Diabetic retinopathy
• Pregnancy and breastfeeding
• Intracranial hypertension

Best Stacking Partners

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

• Injection site reactions
• Mild fatigue post-injection
• Transient flushing
• Muscle soreness (exercise-mimetic effect)

Contraindications

• Pregnancy and breastfeeding
• Type 1 diabetes (insulin sensitivity changes require monitoring)
• Not FDA-approved
• Limited human safety data
• Active cancer (metabolic pathway activation)

Best Stacking Partners